Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 1071 • ACR Convergence 2023
No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)
Madeline O'Sullivan¹, Grant Cannon¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel⁴, Jessica A Walsh⁵, Punyasha Roul⁶, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten⁴, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴University of Utah, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
Abstract Number: 1079 • ACR Convergence 2023
Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements
Tawnie Braaten¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵ and Grant Cannon⁵, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune Checkpoint Inhibitor (ICI)-induced myositis (ICI-myositis) is a rare, but potentially fatal complication of ICI therapy.Electronic health record (EHR) databases are essential to accrue…
Abstract Number: 1149 • ACR Convergence 2023
Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Tessalyn Morrison¹, Taylor Lakusta-Wong¹, Chantal Roy-Hewitson¹, Jeanne Gosselin² and Alana Nevares³, ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Waterbury, VT, ³University of Vermont, Essex Junction, VT
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…
Abstract Number: 0047 • ACR Convergence 2023
Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis
Marie Robert¹, Nader Yatim², Arthur Mageau³, Nicolas Charles⁴, Tiphaine Goulenok², Tom Dott¹, Violaine Saint Andre¹, Darragh Duffy¹ and Karim Sacre³, ¹Institut Pasteur Paris, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France, ³Université Paris Cité, Paris, France, ⁴INSERM, Paris, France
Background/Purpose: Sarcoidosis is an inflammatory disease characterized by granuloma tissue lesions that most commonly affect the lungs, but can target any other organ. While the…
Abstract Number: 1153 • ACR Convergence 2023
Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches
Manush Sondhi¹, Warda Maqsood² and Sarwat Umer³, ¹Louisiana State University, Shreveport, LA, ²LSU Health Science Center, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA
Background/Purpose: SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a relatively rare and often underdiagnosed inflammatory disorder. Its diagnosis can be challenging due to its…
Abstract Number: 0126 • ACR Convergence 2023
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
Abstract Number: 1656 • ACR Convergence 2023
Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)
anna Fryxelius¹, Amy Martinsen², Ida Løchting³, Linda Aimee Hartford Kvæl⁴, Astrid Lunestad², Astrid Bergland⁴ and Kjersti Storheim², ¹Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ⁴OsloMET, Oslo, Norway
Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
Abstract Number: 0252 • ACR Convergence 2023
Characterizing Granulomatous Mastitis: A Retrospective, Single-Institutional Case Series of a Racially and Ethnically Diverse Cohort
Lindsay Pattison¹, Bibi Ayesha², Anand Kumthekar³, Maureen McEvoy², Beth McLellan² and Inessa Gendlina², ¹Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Granulomatous mastitis (GM) is a rare, chronic, inflammatory breast condition characterized by granulomatous inflammation affecting mainly minority women of childbearing age. Patients present with…
Abstract Number: 1806 • ACR Convergence 2023
The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis
Daming Shao¹, Jiyoung Seo¹, Shaunak Mangeshkar¹, Natalia Nazarenko¹, Stepan Esagian¹, Leonidas Palaiodimos¹ and Damianos Kokkinidis², ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Yale University School of Medicine, New Haven, CT
Background/Purpose: Cardiac sarcoidosis (CS) results from granulomatous infiltrating of the myocardium and manifests as an extended clinical spectrum from silence to conduction disturbances, ventricular tachyarrhythmias,…
Abstract Number: 0262 • ACR Convergence 2023
Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients
Xavier Puéchal¹, Philippe Blanche², Olivier Fogel³, Omar Al Tabaa⁴, Roba Ghossan⁴, Xavier Ayral⁴, Jerome AVOUAC⁵, Maxime Breban⁶ and Yannick ALLANORE⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Department of Rheumatology, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁶Department of Rheumatology, Boulogne-Billancourt, France, ⁷Université Paris Cité, Paris, France
Background/Purpose: Whipple disease is a chronic, curable, systemic bacterial infection caused by Tropheryma whipplei. The classic form usually begins with recurrent arthritis, followed years later…
Abstract Number: 1851 • ACR Convergence 2023
Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar
Chiara Gasteiger¹, Maria Lobo², Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Transitioning patients with rheumatic diseases to biosimilars has become common to reduce healthcare costs and improve patient access to biologic therapies. However, it is…
Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Greta Mastrangelo¹, Ellen Go², Paul Tsoukas², Hua Lu³, Amy Xu², Arthur Hoi Hin Cheng² and Rae Yeung⁴, ¹The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, ²The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
Abstract Number: 033 • 2023 Pediatric Rheumatology Symposium
Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)
Lyndsey Cole, Marsha Anderson, Heather Heizer, Michelle Hite, Christina Osborne, Samuel Dominguez and Pei-Ni Jone, University of Colorado School of Medicine, Denver, CO
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory illness associated with SARS-CoV-2 infection and has overlapping features with Kawasaki Disease (KD). The objective…
Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Daniel Ibanez¹, Bianca Lang², Ali Yalcindag³, Linda Wagner-Weiner⁴, Julia Shalen⁵, Kenneth Schikler⁶, Shoghik Akoghlanian⁷, Hulya Bukulmez⁸, Kristen Hayward⁹, Sivia Lapidus¹⁰, Andrea Ramirez¹¹, Robert Sundel¹, Cagri Yildirim-Toruner¹² and CARRA Registry Investigators¹³, ¹Boston Children's Hospital, Boston, MA, ²Dalhousie University - Halifax, Halifax, NS, Canada, ³Hasbro Children's Hospital, Milton, MA, ⁴The University of Chicago, Chicago, IL, ⁵Johns Hopkins University, Baltimore, MD, ⁶University of Louisville School of Medicine Norton Children's Hospital, Louisville, KY, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ⁹Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, ¹⁰Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹¹Baylor College of Medicine, Houston, TX, ¹²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ¹³CARRA, Washington, DC
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…
Abstract Number: 080 • 2023 Pediatric Rheumatology Symposium
Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)
Yoel Levinsky¹, Oded Scheuerman², Rotem Tal³, Gil Amarilyo³ and Liora Harel³, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Pediatric B department, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel
Background/Purpose: Interferonopathies are a recently recognized group of genetic syndromes associated with uncontrolled activation of interferon. PRAAS (proteasome-associated autoinflammatory syndromes) is an interferonopathy caused by…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].